This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.
The distinction that matters is unopened versus in use. Unopened vials are stable refrigerated for their labelled shelf life and tolerate a limited excursion to room temperature. Once reconstituted, the clock is much shorter and is set by the preservative rather than by the peptide — bacteriostatic water's benzyl alcohol is what buys you multiple draws over weeks. Sterile water has no preservative and turns a multi-dose vial into a single-use one.
Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.
What I am trying to establish is what a temperature excursion actually does, and what distinguishes an unopened vial from one already in use. Not looking for reassurance. Looking for the part I have got wrong.
kate.chem said:The distinction that matters is unopened versus in use.
Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.
kate.chem said:The distinction that matters is unopened versus in use.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Freezing is the one to avoid, and freeze-thaw more so. Ice-crystal formation and the concentration changes at the phase boundary drive aggregation, and aggregated peptide does not recover on thawing. A vial that has been frozen and thawed is not rescued by returning it to the fridge.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemThis one has a reasonably settled answer, so here it is. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.
TrialNerd_Beth said:Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured…
Mine went the same way, slower. The detail I would add is minor and it is already implied above.